This paper reports on the synthesis and characterization of two Schiff bases bearing 1,2,4-triazolic moieties, namely 4H-4-(2-hydroxy-benzylidene-amino)-5-benzyl-3-mercapto-1,2,4-triazole and 4H-4-(4-nitro-benzylidene-amino)-5-benzyl-3-mercapto-1,2,4-triazole using thin layer chromatography, melting interval, elemental analysis, spectroscopy and thermal stability studies.
Betulonic acid belongs to the pentacyclic triterpenic derivative class and can be obtained through the selective oxidation of betulin. In this study we set obtaining several functionalized derivatives of this compound by its condensation with several amino compounds such as aminoguanidine, hydroxylamine, n-butylamine and thiosemicarbazide as our goal. The functionalization of the parent compound led to several molecules with antiproliferative potential, the most promising being 3–2-carbamothioylhydrazonolup-20(29)-en-28-oic acid.
Itraconazole is an antifungal agent included in the triazole pharmacological classification that belongs to the BCS class II, characterized by a low solubility in an aqueous medium (of 1 ng/mL, at neutral pH), which is frequently translated in a low oral bioavailability but with a high permeability. In this sense, it is necessary to find solutions to increase/improve the solubility of itraconazole in the aqueous environment. The main purpose of this study is the preparation and analysis of five different guest–host inclusion complexes containing intraconazole. Initially, a blind docking process was carried out to determine the interactions between itraconazole and the selected cyclodextrins. The second step of the study was to find out if the active pharmaceutical ingredient was entrapped in the cavity of the cyclodextrin, by using spectroscopic and thermal techniques. Also, the antifungal activity of the inclusion complexes was studied to examine if the entrapment of itraconazole influences the therapeutic effect. The results showed that the active substance was entrapped in the cavity of the cyclodextrins, with a molar ratio of 1:3 (itraconazole–cyclodextrin), and that the therapeutic effect was not influenced by the entrapment.
6 July 2020 in Journal of Thermal Analysis and Calorimetry
Mupirocin is a topical antibiotic widely used to treat various skin infections caused by Gram-positive and Gram-negative bacteria, being the first-line treatment in the case of an infection with methicillin-resistant Staphylococcus aureus (MRSA). Due to the unique mechanism of action, it does not possess any cross-resistance with other antibiotics, leading to its global use in different hospital departments. The main disadvantage of mupirocin is represented by its pharmacokinetic properties, leading to the main purpose of this study, namely, to fully characterize the physicochemical properties of the active pharmaceutical ingredient. Currently, it is used in different combinations with other active substances, for example metronidazole, to decrease the risk of developing resistance to mupirocin and to improve the therapeutic response. This leads to the second purpose of this study, i.e., to characterize the physico-chemical profile of metronidazole and to find out if there are any chemical interactions between the two compounds, and to establish if there is a possibility of using them in the same pharmaceutical formulation, thus increasing the compliance of the patient to the treatment.
19 August 2018 in Journal of Thermal Analysis and Calorimetry